

Supporting Information

Improved Survival Rate and Minimal Side Effects of Doxorubicin for Lung Metastasis using Engineered Discoidal Polymeric Particles

Sanghyo Park^{a§}, Hyungkyu Park^{a§}, Chaewon Park^a, Wan Su Yun^{b,c}, Soonjae Hwang^{d,e}, Hong Yeol Yoon^{b,c}, Ick Chan Kwon^{b,c}, Kwangmeyung Kim^{b,c}, Jaehong Key^{a*}

Contents


Supporting Figures

Figure S1 In vivo fluorescent images of metastatic lung cancer induced by SCC7.


Figure S2 Ex vivo fluorescence images 24 h after DOX-DPP injection in SCC7-induced metastatic lung cancer.

Figure S3 Mean number of nodules in each group.


Table S1 Drug content in DOX-DPPs according to the drug input.



Supplemental Figure 1. (A, B) In vivo fluorescent images of metastatic lung cancer induced by SCC7 measured as the GFP signal. (C) Biodistribution of DOX-DPP via intravenous injection measured as the DOX signal.



Supplemental Figure 2. Ex vivo fluorescence images 24 h after DOX-DPP injection in SCC7-induced metastatic lung cancer.



Supplemental Figure 3. Mean number of nodules in each group.

Supplemental Table 1. Loading content for DOX-DPPs

PLGA (mg)	Doxorubicin (mg)	Loading content (%)
70	5	12.95 ± 0.88
70	9	23.44 ± 0.64
70	15	23.10 ± 0.9